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Prenatal and postnatal 




Aim. To determine prenatal and postnatal risk factors for developing bronchopulmonary dysplasia in infants < 30 weeks of 
gestational age.
Methods. Over a 22-month period, 115 newborns were enrolled in the study. Details including gestational age, sex, birth 
weight, prenatal steroids, surfactant treatment, ventilatory support, days of postnatal oxygen requirement, late onset sepsis/
pneumonia, air leaks, patency of ductus arteriosus, and fluid intake were collected. The presence of chorioamnionitis was 
diagnosed by histological examination. Commercial ELISA kits were used for the determination of the IL-6 and IL-8 levels. 
Results. Twenty-five infants developed BPD and 90 were enrolled in the non BPD group. Lower gestational age and male sex 
increased the risk for BPD. There was no difference in the presence of chorioamnitis and the level of IL-6 and IL-8 measured 
in cord blood and gastric aspirate between the groups. Intubation in the delivery room (resuscitation), need for surfactant 
treatment, mechanical ventilation, late onset sepsis/pneumonia, increased oxygenation index increased the risk for BPD after 
adjustment for GA and gender.
Conclusion. In our cohort of infants with GA < 30 weeks exposure to prenatal inflammation did not increase the risk for BPD. 
However, low gestational age, male sex, need for resuscitation, mechanical ventilation and late onset sepsis were major risk 
factors for BPD development.
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Introduction
Bronchopumonary dysplasia (BPD) 
was first described by Northway in 1967 
(1) reporting clinical and radiographic 
changes in the lungs of preterm infants 
who had respiratory distress syndrome 
(RDS) and who were treated with oxy-
gen and mechanical ventilation. Beside 
risks of mechanical ventilation (duration, 
volu-, barotrauma and oxidative stress) 
also nosocomial infections and pat-
ent ductus arteriosus had been clearly 
identified as risk factors for BPD devel-
opment (2,3,4). The study from Watter-
berg et al. (5) in 1996 established that 
that the presence of chorioamnionitis 
(CHA) was associated with lower inci-
dence of RDS and higher of BPD, indi-
cating that lung injury can start before 
birth. Later studies confirmed that CHA 
(6,7,8) funisitis (9), and fetal inflamma-
tory response syndrome (10,11) were 
associated with increased incidence of 
BPD; however, results were not repro-
duced in some later studies (12,13). 
It has been suggested that the asso-
ciation between CHA and BPD is more 
complicated (14). Van Marter et al. (15) 
introduced “multiple hit” theory. They 
established that CHA does not increase 
the incidence of BPD by itself, but only 
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in combination with already known risk 
factors for BPD, such as mechanical 
ventilation longer than 7 days and expo-
sure to postnatal infection. 
Most of the published studies were 
focused on identifying either prenatal 
or postnatal risk factors. The aim of this 
study was to identify prenatal and post-
natal risk factors in a cohort of infants 
with GA < 30 weeks.
Material and methods
All infants delivered at less than 30 
weeks of gestation in the Ljubljana 
Maternity Hospital, a tertiary referral 
centre for premature infants in Slov-
enia, during the period from September 
1st, 2000, to June 30th, 2002, were 
enrolled in the study. The eligibility crite-
ria were: 1) inborn infant, 2) availability 
of placenta and cord blood, 3) written 
informed parental consent obtained, 
and 4) absence of obvious congenital 
malformation. The National Medical 
Ethics Committee approved the study. 
Details including gestational age, sex, 
birth weight, prenatal steroids, fluid 
intake, blood pressure, catecholamine, 
indomethacin and surfactant treatment, 
ventilatory support and days of postna-
tal oxygen requirement were collected. 
Gestational age was determined by the 
best obstetric estimate using the last 
menstrual period and/or early ultra-
sound assessment. 
The placenta, including fetal mem-
branes and umbilical cord, was exam-
ined microscopically for the presence 
of inflammation. CHA was defined as 
acute when ten or more polymorphonu-
clear leukocytes were found per high-
power field in the amniotic and chori-
onic membranes, in the chorionic plate, 
and/or in the umbilical cord. Blood was 
collected from the umbilical cord imme-
diately after birth, then centrifuged and 
stored at –70oC until cytokine immu-
noassay was performed. Commercial 
ELISA kits (Endogen-Pierce, Boston, 
USA) were used for determination of the 
IL-6 and IL-8 levels. 
Gastric aspirate sample was collected 
at the time of delivery with a 5F oro-
gastric feeding tube. Because of no 
reliable correction factor available (16), 
cytokine concentrations in gastric aspi-
rates were expressed as volume con-
centrations (pg/ml or ng/ml).
Infants with RDS on artificial ventilation 
(FiO2 > 0.60 and oxygenation index 
(OI) > 20 (OI = (MAPxFiO2x100)/paO2, 
MAP mean airway pressure, FiO2 frac-
tion of inspired oxygen, paO2 partial 
pressure of oxygen in arterial blood) 
were treated with exogenous surfactant 
(poractant alpha, Curosurf®, 100 mg/
kg body weight). Pulmonary air leak 
(PAL) was confirmed by X-ray. Late 
onset sepsis/pneumonia (LOS/P) was 
confirmed by isolation of the organism 
from the blood or cerebrospinal fluid/
tracheal aspirate later than 72 hours of 
life. Patent ductus arteriosus (PDA) was 
diagnosed clinically and confirmed by 
echocardiography.
BPD was diagnosed according to 
National Information Health Center as 
oxygen dependency at 36 weeks of GA. 
Target saturation was kept between 
88-92 %.
Statistical analysis. The T-test or Mann-
Whitney U test were used for compari-
son of continuous variables that were 
normally or not normally distributed. 
The Pearson chi-square test or Fisher’s 
exact test (both 2-sided) were used for 
comparison of categorical variables as 
appropriate. Logistic regressions were 
performed stratified by GA. The results 
were presented as mean ± standard 
deviation (SD) or median with interquar-
tile range (IQR) or odds ratio (OR) with 
a 95 % confidence interval (CI). P value 
< 0.05 was selected to determine sta-
tistical significance. Statistical Package 
of Social Sciences, version 14.0 (SPSS 
Inc., Chicago, USA) was used for the 
statistical analyses.
Results
One hundred and fifteen infants (89.1 
%) with GA < 30 weeks survived and 
met the eligibility criteria, from a total 
of 129 born during the study period. 
Among the survivors, 25 (21.7 %) 
infants developed BPD. Male infants 
comprised 53.0 % of the study group. 
Mean 1-minute Apgar score was 6 
(range, 47) and mean 5-minute Apgar 
score was 7 (range, 68). Ninety-three 
(80.8%) infants received prenatal corti-
costeroids (39 incomplete and 54 com-
plete courses).  
General characteristics of the study 
group are shown in Table 1. Infants who 
developed BPD had lower birth weight 
and gestational age. The percentage 
of males was higher in the BPD group. 
The average length of hospitalization 
was 1.7 times longer in the BPD group 
when compared to the non BPD group, 
despite the average difference in GA 
between the groups being 1 week only. 
The mode of delivery, prenatal corticos-
teroid therapy, 1 and 5 min Apgar score 
and number of multiples did not differ 
between the groups. Figure 1 shows 
percentages for death, survival with 
BPD, and survival without BPD for each 
week of gestational age. In the group 
of infants with GA  24 weeks, survival 
without BPD was very low (7.1 %). This 
was followed with progressive increase 
in survival without BPD for each week of 
GA; survival without BPD in the group 
of infants with GA of 29 weeks already 
reached 83.3 %. 
Table 2 shows the comparison of the 
level of measured cytokines between 
the BPD and non BPD group. There 
was no difference in clinical, histo-
logical chorioamnionitis, and funisitis 
between the study groups. The level of 
IL-6 and IL-8 in cord blood and gastric 
aspirate was also similar in both study 
groups. Separate analysis of all infants 
with analyzed placenta for the presence 
of histological chorioamnionitis showed 
that infants with histologicaly confirmed 
chorioamnionitis after adjustment for 
GA less likely developed RDS (OR 0.32 
[0.140.76], p=0.009), however there 
was no difference in the development 
of BPD.
Table 3 shows the difference in resusci-
tation measures and ventilatory support 
between infants with BPD and infants 
without BPD. Infants who developed 
BPD were more often resuscitated in 
the delivery room, more often needed 
intubation and surfactant treatment. 
Infants who developed BPD were venti-
lated with higher maximal peak inspira-
tory pressure (MIP), and needed higher 
FiO2. The length of mechanical ventila-
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tion and oxygen supplementation was 
significantly longer in the BPD group 
when compared to non BPD group. 
Infants who developed BPD also had 
more PAL and more often suffered from 
LOS/P.
Table 4 shows that infants who devel-
oped BPD had more often echoca-
diographically confirmed PDA and had 
higher fluid intake on day 2 when com-
pared to infants without BPD. The need 
for cathecholamine treatment was also 
higher in the BPD group.
Risk factors for BPD development calcu-
lated with regression multivariate model 
are presented in Figure 2. Factors that 
independently increased risk for BPD 
development were: need for intubation 
in the delivery room, level and length of 
mechanical ventilation support (MAP, 
gen deposition in the adventitia of small 
pulmonary arteries (19). These results 
support the “Watterberg effect” (5). Stu-
dies confirming association between 
BPD and CHA are mainly from the time 
when the use of prenatal steroids was 
low. The overview through the studi-
es on prenatal inflammation and BPD 
showed significant variations in gesta-
tional age and birth weight ditribution, 
the percentage of prenatal steroid and 
surfactant treatment. It is well known 
that the incidence of CHA and respira-
tory symptoms increase with lower GA. 
Most of the recently published studies 
on choriamnionitis and BPD have not 
confirmed the effect of chorioamnio-
nitis on BPD. Our results have shown 
no influence of CHA, neither funisitis or 
elevated levels of cytokines on BPD, 
but have also shown that prenatal 
exposure to CHA decreases incidence 
of RDS, results similar to other publis-
hed data (20,21,22,23). Moss et al.(24) 
showed in a sheep model that lung 
structure, function, and surfactant sys-
tem were all significantly affected by 
the intra-amnioticaly given endotoxin 
at all stages of pulmonary develop-
ment, but the response itself differed 
depending on the gestational timing. 
The exposure to prenatal inflammation 
increases surfactant synthesis and 
decreases RDS development (25). In 
sheep, lung maturation characterized 
by increased lung volumes and alve-
olar saturated phosphatidylcholine, 
occurred at 7 days after the endotoxin 
injection and persisted for 25 days 
(26). Despite the initial assumption 
that prenatal inflammation reduces the 
risk for RDS by eliciting a fetal cortisol 
surge, Jobe et al (27) showed in a fetal 
sheep model that early lung matura-
tion induced by intra-amniotic endo-
toxin occurred without an increase in 
fetal plasma cortisol, which indicated 
that endotoxin promoted lung matu-
ration by a mechanism independent 
of cortisol. Morphometric lung analy-
ses in the sheep model showed that 
alveolar wall thickness was reduced 
in the sheep treated with endotoxin 
at the time of transition to the canal-
icular stage (25). Kramer at al. (28) 
MIP, OI), need for surfactant replace-
ment treatment, the presence of PDA, 
and development of LOS/P.
Discussion
In our cohort of infants with GA < 30 
weeks, prenatal and postnatal risk fac-
tors for BPD development were studied. 
As expected, the risk for BPD declined 
with increased gestational age. Prena-
tal inflammation (chorioamnionitis and 
exposure to cytokines) did not increase 
the risk for BPD development. Need 
for resuscitation with early intubation in 
the delivery room, need for surfactant 
replacement treatment, the length and 
level of ventilatory support, develop-
ment of LOS/P, and the presence of 
PDA increased the risk for BPD. 
Male gender increases the risk for death 
in low birth weight populations (17). Inc-
reased incidence of BPD in males can 
be partly explained by higher oxidative 
stress and lower antioxidant activity in 
male preterms (18). 
Previously published data show that 
low gestational age (the stage of pul-
monary development) is one of the cru-
cial risk factors for BPD development. In 
animal studies, it was established that 
intra-amniotic application of endotoxin 
on the one hand induces maturation of 
fetal lungs but on the other hand inhibits 
alveolarisation of the lungs and causes 
muscularisation of the media and colla-
Table 1. Characteristics of infants with and without BPD. Results as percent-






Birth weight  (g) 1088 (212) 841 (216) <0.001
GA (wks) 27.5 (1.3) 26.4 (1.9) 0.001
male (%) 40.7 66.7 0.027
1-minute Apgar score<3 (%) 6.7 12.0 0.30
5-minute Apgar score<5 (%) 6.7 4.0 0.52
Prenatal dexamethason (%) 81.1 80.0 1.0
Vaginal delivery (%) 56.7 64.0 0.64
Multiple pregnancies (%) 25.1 32.6 0.61
Hospital days 63 (16) 110 (24) <0.001
GA, gestational age; BPD bronchopulmonary dysplasia.
BPD , bronchopulmonary dysplasia; GA, 
gestational age.
Figure 1. Mortality and survival in 
infants with/without BPD with res-
pect to GA at birth. 
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showed in bitransgenic mice that peri-
natal increase in TGF- disrupted the 
saccular phase of lung morphogen-
esis and caused remodeling, charac-
terized by mesenchymal thickening, 
vascular remodeling, and poor apposi-
tion of capillaries to distal air spaces 
after; however, surfactant levels were 
not reduced. Pathological changes 
in TGF--overexpressing mice bore 
similarities to premature infants born 
in the saccular phase who developed 
BPD.  In addition to results from animal 
experiments, very similar results were 
found in a clinical study from Viscardi 
et al (29). They found that histologi-
cal CHA was significantly associated 
with BPD in infants less than 28 weeks 
gestation at birth, but not in infants with 
gestational age above 28 weeks. The 
percentage of CHA in our study was 
in the range of previously published 
studies. As shown in overview from 
Beer and Zimmerman (30), the incre-
ased incidence of BPD after prenatal 
inflammation was reproduced in 6 of 18 
studies; furthermore, in only one study 
the results were adjusted for gestatio-
nal age (31). Beside the importance of 
when the fetus is exposed to prenatal 
inflammation, the time of exposure to 
the intra-amniotic endotoxin is also 
important. Kallapur et al (32) estab-
lished that continuous exposure to the 
intra-amniotic endotoxin, in contrast to 
single, did not cause sustained struc-
tural abnormalities in fetal sheep lungs. 
The most probable reason for not con-
firming positive association between 
prenatal inflammation and BPD in our 
study was high percentage of prenatal 
steroids, as already suspected in the 
overview of Beer and Zimmerman (30). 
Similarly to other clinical settings it was 
also impossible to quantify the dura-
tion of fetal exposure to infection and 
inflammation.
The association of BPD and mechani-
cal ventilation is well described. Artificial 
ventilation is causing damage with high 
peak inspiratory pressures and high 
percentage of inhaled oxygen, causing 
the formation of oxygen radicals. Besi-
de GA, gender and PDA, resuscitation 
measures and mechanical ventilation 
Table 2. Comparison of the level of measured cytokines between the groups. 







































CHA, chorioamnionitis; IL-6, interleukin-6; IL-8, interleukin-8.
Table 3. Differences in resuscitation measures and ventilatory support between 















Surfactant (%) 34.5 92.0 <0.001
PAL (%) 3.5 20.0 0.014
LOS/P (%) 10.4 68.0 <0.001
Max MIP (cm H2O) 21.9 (4.9) 25.3 (4.8) 0.012
Max PEEP (cm H2O) 3.5 (1.1) 3.7 (1.2) 0.48
Max MAP (cm H2O) 9.8 (2.5) 11.8 (2.2) 0.030
Max OI 12.0 (8.6) 18.9 (10.0) 0.013
Max FiO2; 49.6 (24.9) 69.3 (23.5) 0.002
Days of mechanical venti-
lation
7.1 (8.8) 37.1 (19.1) <0.001
Days on oxygen 20 (20) 105 (26) <0.001
First breathing room air 
(days) 
4.5 (6) 62 (60) <0.001
DR, delivery room; FiO2, fraction of inspired oxygen; LOS/P, late onset sepsis/pneumonia; 
MAP, mean airway pressure; MIP, maximal inspiratory pressure; OI, oxygenation index; PAL, 
pulmonary air leak; PEEP, positive end-expiration pressure
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Table 4. Patent ductus arteriosus, indomethacin and cathecholamine treat-
ment and fluids during first three days in infants without and with BPD. Results 













Day 1 fluids 
(ml/kg BW)
89 (15) 92 (11) 0.32
Day 2 fluids 
(ml/kg BW)
96 (10) 102 (13) 0.03
Day 3 fluids 
(ml/kg BW)
106 (10) 107 (14) 0.56
Weight loss 
on day 3 (%)
10.3 7.8 0.11
PDA, persistent ductus arteriosus; BW, body weight
BPD, bronchopulmonary dysplasia; GA, 
gestational age; LOS/P, late onset sep-
sis/pneumonia; MAP, mean airway pres-
sure; MIP, maximal inspiratory pressure; 
OI, oxygenation index; OR, odds ratio; MV, 
mechanical ventilation; PDA, patent ductus 
arteriosus
Figure 2. OR (95 % CI) for BPD devel-
opment in our cohort of infants with 
GA < 30 weeks (variable adjusted for 
GA and gender). 
high concentrations in tracheal aspirate 
fluid of infants developing BPD (38). 
Analysing prenatal and postnatal risk 
factors for BPD in our cohort of infants 
with GA < 30 wks, prenatal inflammation 
was not identified as a risk factor for 
BPD. Beside already known measures 
of how to decrease the incidence of BPD 
(prenatal corticosteroid treatment, early 
surfactant treatment) we should work 
further on 1) prevention of preterm birth, 
2) additional studies on the resuscitation 
of preterm infants, 3) shortening the time 
of mechanical ventilation, 4) alternati-
ve ventilation strategies, 5) monitoring 
and treatment of oxidative stress during 
mechanical ventilation, 6) prevention 
of postnatal sepsis/pneumonia, and 7) 
monitoring for hemodynamic PDA.
cantly higher in the BPD group than in 
non BPD group and PDA was shown 
to be independent risk factor for BPD 
development also in our study. The 
intake of fluids on day 2 was also signi-
ficantly higher in the BPD group when 
compared to the non BPD group. The 
effect of fluids on BPD development 
was probably indirect  through keeping 
the PDA open (36).  
In mice intermittent hypoxic stress 
increases hyperoxia induced damage 
of lung tissue and exacerbates alveolar 
developmental arrest (37). There are 
similarities between inflammation and 
hypoxia/reoxygenation, since both acti-
vate a number of inflammatory media-
tors such as cytokines and adhesion 
molecules, some of which are found in 
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